Search research articles
Contact Us
Filters
Showing results (161-170 of 189) with videos related to
Page
of 19
Sort By:
Blood Advances
|
January 4, 2018
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis
Prajwal Boddu, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.
Leukemia
|
July 1, 2017
BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
B Sun, W Fiskus, Y Qian, et al.
Blood Cancer Journal
|
January 17, 2019
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
Warren Fiskus, Tianyu Cai, Courtney D DiNardo, et al.
Blood
|
February 24, 2026
Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor
Warren Fiskus, Christopher P Mill, Ghayas C Issa, et al.
Leukemia
|
November 24, 2012
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
E Jabbour, P D le Coutre, J Cortes, et al.
Blood Advances
|
August 19, 2025
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phase
Warren Fiskus, Lucia Masarova, Christopher P Mill, et al.
Blood
|
November 25, 2010
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Hagop M Kantarjian, Francis J Giles, Kapil N Bhalla, et al.
Virchows Archiv : an International Journal of Pathology
|
March 2, 2023
Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant
Siba El Hussein, L Jeffrey Medeiros, Stephen K Gruschkus, et al.
Plos One
|
October 8, 2010
Genome-wide DNA methylation maps in follicular lymphoma cells determined by methylation-enriched bisulfite sequencing
Jeong-Hyeon Choi, Yajun Li, Juyuan Guo, et al.
Leukemia
|
January 3, 2017
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
D T Saenz, W Fiskus, Y Qian, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 189) with videos related to
Sort By:
Page
of 19
Blood Advances
|
January 4, 2018
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis
Prajwal Boddu, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.
Leukemia
|
July 1, 2017
BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
B Sun, W Fiskus, Y Qian, et al.
Blood Cancer Journal
|
January 17, 2019
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
Warren Fiskus, Tianyu Cai, Courtney D DiNardo, et al.
Blood
|
February 24, 2026
Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor
Warren Fiskus, Christopher P Mill, Ghayas C Issa, et al.
Leukemia
|
November 24, 2012
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
E Jabbour, P D le Coutre, J Cortes, et al.
Blood Advances
|
August 19, 2025
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phase
Warren Fiskus, Lucia Masarova, Christopher P Mill, et al.
Blood
|
November 25, 2010
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Hagop M Kantarjian, Francis J Giles, Kapil N Bhalla, et al.
Virchows Archiv : an International Journal of Pathology
|
March 2, 2023
Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant
Siba El Hussein, L Jeffrey Medeiros, Stephen K Gruschkus, et al.
Plos One
|
October 8, 2010
Genome-wide DNA methylation maps in follicular lymphoma cells determined by methylation-enriched bisulfite sequencing
Jeong-Hyeon Choi, Yajun Li, Juyuan Guo, et al.
Leukemia
|
January 3, 2017
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
D T Saenz, W Fiskus, Y Qian, et al.
Page
of 19